Efficacy and safety of dronedarone in patients previously treated with other antiarrhythmic agents.

ABSTRACT:

Background

Currently available antiarrhythmic drugs (AADs) for the prevention of atrial fibrillation (AF)/atrial flutter (AFL) suffer from incomplete efficacy and poor tolerability.

Hypothesis

Dronedarone could represent an effective and safe option in patients previously treated with AADs, especially class Ic AADs and sotalol.

Methods

Retrospective analysis of 2 double-blind, parallel-group trials (EURIDIS [European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm] and ADONIS [American-Australian-African Trial With Dronedarone in Atrial Fibrillation or Flutter Patients for the Maintenance of Sinus Rhythm]) comparing the efficacy and safety of dronedarone with placebo over 12 months. The primary end point was A

SUBMITTER: Guerra F 

PROVIDER: S-EPMC6647669 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature